Spots Global Cancer Trial Database for cabergoline
Every month we try and update this database with for cabergoline cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | NCT01794793 | Cushing's Disea... Acromegaly Neuroendocrine ... Pituitary Tumor... Ectopic ACTH Se... Dumping Syndrom... Prostate Cancer Melanoma Negati... Melanoma Negati... | Pasireotide Cabergoline Pasireotide | 18 Years - | RECORDATI GROUP | |
| Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma | NCT03457389 | Pituitary Adeno... Prolactinoma Pituitary Tumor Recurrence Tumo... | Cabergoline | 19 Years - | Seoul National University Hospital | |
| Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma | NCT03457389 | Pituitary Adeno... Prolactinoma Pituitary Tumor Recurrence Tumo... | Cabergoline | 19 Years - | Seoul National University Hospital | |
| Cabergoline in Metastatic Breast Cancer | NCT01730729 | Recurrent Breas... Stage IV Breast... | cabergoline | 18 Years - | Northwestern University | |
| Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease | NCT01915303 | Cushings Diseas... | Pasireotide wit... | 18 Years - | Novartis | |
| Ovarian Hyperstimulation Syndrome and Cabergoline | NCT01569256 | Polycystic Ovar... Ovarian Hyperst... | Cabergoline | 23 Years - 35 Years | Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital | |
| Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS | NCT05981742 | Polycystic Ovar... | Metformin Hydro... Cabergoline 0.5... Metformin Hydro... | 18 Years - 40 Years | Al-Rasheed University College | |
| Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | NCT01620138 | Non-functioning... Prolactinomas | Pasireotide cabergoline | 18 Years - | Universidade Federal do Rio de Janeiro | |
| Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS | NCT05981742 | Polycystic Ovar... | Metformin Hydro... Cabergoline 0.5... Metformin Hydro... | 18 Years - 40 Years | Al-Rasheed University College | |
| Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | NCT01620138 | Non-functioning... Prolactinomas | Pasireotide cabergoline | 18 Years - | Universidade Federal do Rio de Janeiro | |
| Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas | NCT02288962 | Pituitary Neopl... Adenoma | cabergoline | 18 Years - 75 Years | St. Olavs Hospital | |
| Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome | NCT02644304 | Female Reproduc... | Clomiphene citr... Cabergoline Placebo | 20 Years - 40 Years | Woman's Health University Hospital, Egypt | |
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | NCT01794793 | Cushing's Disea... Acromegaly Neuroendocrine ... Pituitary Tumor... Ectopic ACTH Se... Dumping Syndrom... Prostate Cancer Melanoma Negati... Melanoma Negati... | Pasireotide Cabergoline Pasireotide | 18 Years - | RECORDATI GROUP | |
| Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor | NCT00889525 | Cushing's Disea... Corticotroph Ad... | Cabergoline | 12 Years - | Seth Gordhandas Sunderdas Medical College | |
| Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome | NCT02644304 | Female Reproduc... | Clomiphene citr... Cabergoline Placebo | 20 Years - 40 Years | Woman's Health University Hospital, Egypt | |
| Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor | NCT00889525 | Cushing's Disea... Corticotroph Ad... | Cabergoline | 12 Years - | Seth Gordhandas Sunderdas Medical College | |
| Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome | NCT02644304 | Female Reproduc... | Clomiphene citr... Cabergoline Placebo | 20 Years - 40 Years | Woman's Health University Hospital, Egypt | |
| Cabergoline in Nonfunctioning Pituitary Adenomas | NCT03271918 | Pituitary Adeno... Nonfunctioning ... | Cabergoline | 18 Years - 75 Years | University of Sao Paulo General Hospital | |
| Cabergoline in Metastatic Breast Cancer | NCT01730729 | Recurrent Breas... Stage IV Breast... | cabergoline | 18 Years - | Northwestern University | |
| Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | NCT01620138 | Non-functioning... Prolactinomas | Pasireotide cabergoline | 18 Years - | Universidade Federal do Rio de Janeiro |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
